Scholarlink

Purpose <p>To investigate whether whole-brain (WB) metabolic activity measured on pretreatment [18&#xa0;F]FDG PET/CT provides prognostic information beyond global metabolic tumour burden in patients with breast cancer.</p> Methods <p>This single-centre retrospective cohort included 358 patients with biopsy-confirmed breast cancer who underwent pretreatment [18&#xa0;F]FDG PET/CT for staging. WB SUVmean, WB SULmean, and total metabolic tumour volume (TMTV) were measured using a semi-automated PET/CT analysis workflow. The primary endpoint was overall survival (OS). Sequential Cox models evaluated the incremental prognostic value of WB SUVmean beyond clinical variables and TMTV; WB SULmean was assessed in sensitivity analysis.</p> Results <p>Complete-case data were available for 354 patients. In univariable analysis, higher TMTV was associated with worse OS (HR 1.167 per 100 mL; <i>P</i> &lt; 0.001), whereas higher WB SUVmean (HR 0.785; <i>P</i> &lt; 0.001) and WB SULmean (HR 0.733; <i>P</i> &lt; 0.001) were associated with better OS. After adjustment for age, body mass index, disease extent, fasting glucose, and TMTV, WB SUVmean remained independently associated with OS (HR 0.810, 95% CI 0.679–0.967; <i>P</i> = 0.019), while TMTV retained prognostic value (HR 1.104, 95% CI 1.053–1.157; <i>P</i> &lt; 0.001). WB SULmean showed similar results in sensitivity analysis (HR 0.764, 95% CI 0.586–0.997; <i>P</i> = 0.047). Combined TMTV/WB SUVmean stratification identified three prognostic groups (global log-rank <i>P</i> = 2.14 × 10⁻¹⁰).</p> Conclusion <p>Pretreatment WB metabolic activity provides prognostic information beyond global metabolic tumour burden in breast cancer and may represent a complementary host-related prognostic signal, although the underlying biological mechanisms require further validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Whole-brain metabolic activity on pretreatment [18 F]FDG PET/CT provides prognostic information beyond metabolic tumour burden in patients with breast cancer

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Mehmet Tarık Tatoğlu,
  • Burak Canıtez,
  • Hatice Uslu,
  • Ebru İbişoğlu,
  • Ferda Yerdelen Tatoğlu

摘要

Purpose

To investigate whether whole-brain (WB) metabolic activity measured on pretreatment [18 F]FDG PET/CT provides prognostic information beyond global metabolic tumour burden in patients with breast cancer.

Methods

This single-centre retrospective cohort included 358 patients with biopsy-confirmed breast cancer who underwent pretreatment [18 F]FDG PET/CT for staging. WB SUVmean, WB SULmean, and total metabolic tumour volume (TMTV) were measured using a semi-automated PET/CT analysis workflow. The primary endpoint was overall survival (OS). Sequential Cox models evaluated the incremental prognostic value of WB SUVmean beyond clinical variables and TMTV; WB SULmean was assessed in sensitivity analysis.

Results

Complete-case data were available for 354 patients. In univariable analysis, higher TMTV was associated with worse OS (HR 1.167 per 100 mL; P < 0.001), whereas higher WB SUVmean (HR 0.785; P < 0.001) and WB SULmean (HR 0.733; P < 0.001) were associated with better OS. After adjustment for age, body mass index, disease extent, fasting glucose, and TMTV, WB SUVmean remained independently associated with OS (HR 0.810, 95% CI 0.679–0.967; P = 0.019), while TMTV retained prognostic value (HR 1.104, 95% CI 1.053–1.157; P < 0.001). WB SULmean showed similar results in sensitivity analysis (HR 0.764, 95% CI 0.586–0.997; P = 0.047). Combined TMTV/WB SUVmean stratification identified three prognostic groups (global log-rank P = 2.14 × 10⁻¹⁰).

Conclusion

Pretreatment WB metabolic activity provides prognostic information beyond global metabolic tumour burden in breast cancer and may represent a complementary host-related prognostic signal, although the underlying biological mechanisms require further validation.